Erratum to: Which is the best aromatase inhibitor for postmenopausal breast cancer?

被引：0
|
作者：
机构：
来源：
Drugs & Therapy Perspectives | 2001年 / 17卷 / 6期
关键词：
D O I：
10.2165/00042310-200117060-00007
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：15 / 15
相关论文
共 50 条
  • [21] Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer
    Younis, T.
    Rayson, D.
    Dewar, R.
    Skedgel, C.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 293 - 298
  • [22] Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer
    Dowsett, M
    Pfister, C
    Johnston, SRD
    Miles, DW
    Houston, SJ
    Verbeek, JA
    Gundacker, H
    Sioufi, A
    Smith, IE
    CLINICAL CANCER RESEARCH, 1999, 5 (09) : 2338 - 2343
  • [23] In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients
    Geisler, J
    King, N
    Anker, G
    Ornati, G
    Di Salle, E
    Lonning, PE
    Dowsett, M
    CLINICAL CANCER RESEARCH, 1998, 4 (09) : 2089 - 2093
  • [24] Changes in lipid-levels following aromatase inhibitor treatment in early postmenopausal breast cancer
    Lund, M.
    Corn, G.
    Jensen, M-B.
    Petersen, T. S.
    Dalhoff, K.
    Ejlertsen, B.
    Kober, L.
    Wohlfahrt, J.
    Melbye, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S341 - S341
  • [25] Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model
    Jelovac, D
    Macedo, L
    Goloubeva, OG
    Handratta, V
    Brodie, AMH
    CANCER RESEARCH, 2005, 65 (12) : 5439 - 5444
  • [26] Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer
    Philipovskiy, Alexander
    Campbell, Aleli
    Heydarian, Rosalinda
    Castillo, Brenda
    Dwivedi, Alok K.
    Mccallum, Richard
    Aguilera, Renato
    Gaur, Sumit
    Nahleh, Zeina
    ANTICANCER RESEARCH, 2020, 40 (02) : 857 - 864
  • [27] A nationwide data on the cardiovascular protective effect of tamoxifen and aromatase inhibitor in postmenopausal women with breast cancer
    Moon, H-G
    Choi, S. H.
    Park, Y.
    Jung, J. G.
    Ju, Y. W.
    Kim, K. E.
    Kim, Y.
    Lee, E.
    Lee, H-B
    Han, W.
    Noh, D-Y
    Yoon, H-J
    CANCER RESEARCH, 2019, 79 (04)
  • [28] A STUDY OF FADROZOLE, A NEW AROMATASE INHIBITOR, IN POSTMENOPAUSAL WOMEN WITH ADVANCED METASTATIC BREAST-CANCER
    RAATS, JI
    FALKSON, G
    FALKSON, HC
    JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (01) : 111 - 116
  • [29] Acupuncture for the treatment of arthralgia related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients
    Barzaghi, S.
    Gozzo, S.
    Giardina, G.
    Bascialla, L.
    Gueli, R.
    Marcon, I.
    Vallini, I.
    ANNALS OF ONCOLOGY, 2015, 26 : 24 - 25
  • [30] Postmenopausal breast cancer, aromatase inhibitors, and bone health
    Heneghan, H. M.
    McKenna, M.
    Walshe, J.
    Rothwell, J.
    Evoy, D.
    Geraghty, J.
    McDermott, E.
    Prichard, R. S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2016, 185 : 416 - 417
12345